Femasys (FEMY) AI Stock Analysis

• Market Cap: $30.24M
• Dividend Yield: N/A
• Average Volume (3M): 9.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 98.61%
• EPS Growth: -1.98%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.16
• Shares Outstanding: 43,009,995
• 10 Day Avg. Volume: 22,981,147
• 30 Day Avg. Volume: 9,826,700
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 17.24
• Enterprise Value/Gross Profit: 32.10
• Enterprise Value/Ebitda: -1.77
• 1Y Price Target: $5.50
• Price Target Upside: 685.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $0.50 ▼(-28.57% Downside)

Femasys faces significant financial challenges, with persistent losses and cash flow issues being the primary concerns. Technical analysis shows some positive momentum, but the overall financial instability and negative valuation metrics weigh heavily on the stock's outlook.

Positive Factors

Strategic Partnerships

The partnership with Kebomed expands Femasys' market reach in Europe, enhancing its competitive position and supporting long-term growth in the women's health sector.

Product Line Expansion

Expanding the FemSperm product line strengthens Femasys' infertility portfolio, increasing its market presence and providing comprehensive solutions for reproductive health.

Regulatory Approvals

Securing regulatory approval in New Zealand supports Femasys' global expansion strategy, enhancing product credibility and opening new markets for growth.

Negative Factors

Financial Instability

Ongoing financial instability and negative cash flows challenge Femasys' ability to sustain operations and invest in growth, posing a risk to long-term viability.

High Leverage

High leverage limits financial flexibility and increases risk, potentially affecting Femasys' ability to navigate economic downturns or invest in strategic initiatives.

Unprofitability

Persistent unprofitability undermines Femasys' financial health, limiting reinvestment in innovation and growth, and posing a challenge to achieving sustainable operations.

Femasys Business Overview & Revenue Model

Company Description

Femasys (FEMY) is a biotechnology company focused on advancing women's health by developing innovative medical devices and solutions for reproductive health. The company operates primarily in the healthcare sector, specializing in products that address various aspects of female fertility and contraception. Femasys's core offerings include its proprietary systems for non-surgical treatment options, which aim to improve accessibility and effectiveness for women seeking reproductive health solutions.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and systems designed for women's reproductive health. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics that utilize its innovative technologies. Additionally, Femasys may engage in partnerships with other healthcare organizations and distributors to expand its market reach and enhance product visibility. Key revenue streams include product sales from its core offerings and potential licensing agreements or collaborations with larger medical companies that can leverage Femasys's technology in broader applications. The company may also benefit from grants or funding aimed at supporting women's health initiatives, further contributing to its financial performance.

Femasys Financial Statement Overview

Summary

Femasys is facing significant financial challenges, with persistent losses and negative cash flows. Despite some revenue growth, the company struggles with operational inefficiencies and financial instability, requiring urgent improvements in financial health and profitability.

Income Statement

Femasys has shown a slight increase in revenue over the years, but the company remains unprofitable with consistent negative EBIT and EBITDA margins. The net profit margin remains negative, and the revenue growth rate is volatile, suggesting challenges in achieving stable growth.

Balance Sheet

The balance sheet reflects financial instability with a negative equity position in earlier years, improving to positive but weak equity levels recently. The debt-to-equity ratio indicates high leverage, which could pose risks if not managed carefully. The company needs to strengthen its equity base for financial stability.

Cash Flow

Femasys consistently experiences negative operating and free cash flows, indicating operational challenges and a reliance on external financing. The cash flow to net income ratios are unfavorable, emphasizing the company's struggle to generate cash through operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.89M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	1.01M	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-18.34M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-21.02M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	2.43M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	3.22M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	7.85M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	12.27M	10.14M	9.40M	1.65M	2.24M	59.42M
Stockholders Equity	1.51M	2.30M	18.35M	15.24M	26.33M	-51.82M
Cash Flow
Free Cash Flow	-20.41M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.67M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-744.21K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	10.10M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Positive. The current price of 0.7 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.51, and below the 200-day MA of 0.98, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 59.34 is Neutral, neither overbought nor oversold. The STOCH value of 43.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	60 Neutral	$10.51M	1.07	5.90%	―	-4.99%	-19.11%
RVP	53 Neutral	$27.28M	―	-10.80%	―	-0.24%	50.45%
NXGL	52 Neutral	$27.70M	―	-66.08%	―	133.00%	29.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLSS	46 Neutral	$34.84M	―	-123.50%	―	7.84%	-43.00%
FEMY	45 Neutral	$30.24M	―	-329.45%	―	98.61%	-1.98%
POCI	41 Neutral	$32.86M	―	-51.78%	―	-0.07%	-74.60%

Femasys Corporate Events

Femasys Announces $8 Million Public Offering

On August 25, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd. for a public offering of shares and warrants, expecting to raise $8 million. The proceeds will be used for commercial expansion, product development, and general corporate purposes, with the offering set to close on August 27, 2025.

Femasys Gains UK Approval for FemBloc Birth Control

On August 20, 2025, Femasys Inc. announced that it received UK regulatory approval for its FemBloc Permanent Birth Control, a non-surgical solution for permanent birth control. This approval marks a significant milestone in Femasys’ European commercialization strategy, following its recent CE mark for Europe. The approval not only validates FemBloc’s safety and effectiveness but also positions Femasys to secure a strategic partner for commercialization in the UK, a key healthcare market in Europe.

Femasys Enters European Market with Major Spain Order

On August 6, 2025, Femasys Inc. announced its first commercial entry into Europe with a $400,000 order for FemBloc Permanent Birth Control in Spain, marking a strategic milestone in its global expansion. FemBloc, a revolutionary non-surgical permanent contraceptive, offers a less invasive and cost-effective alternative to traditional methods, and its introduction in Spain is supported by partnerships with Comercial Medico Quirúrgica and Durgalab. This development is expected to enhance Femasys’s market positioning and meet growing demand across Europe.

Femasys Faces Nasdaq Noncompliance Notice for Stock Price

On July 16, 2025, Femasys Inc. received a notice from Nasdaq indicating noncompliance with the Minimum Bid Price Requirement, as the company’s stock price had been below $1.00 for 30 consecutive business days. This notification does not immediately affect the trading of Femasys’ stock, but the company has until January 12, 2026, to meet the requirement. Femasys may consider options such as a reverse stock split to regain compliance, but there is no assurance of success.

Femasys Enters Purchase Agreement with Alumni Capital

On June 30, 2025, Femasys Inc. entered into a Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its common stock over a specified period. This agreement provides Femasys with flexibility in financing, contingent on market conditions and trading prices, while ensuring compliance with regulatory requirements and ownership limitations.

Femasys Gains Regulatory Approvals in Australia and New Zealand

On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.

Femasys Approves Director Elections and Share Increase

On June 25, 2025, Femasys Inc. held its Annual Meeting of Stockholders, where approximately 59.41% of the total outstanding shares were represented. During the meeting, stockholders approved the election of two Class I directors, an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000, and ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.

Femasys Gains European Approval for FemBloc System

On June 25, 2025, Femasys Inc. announced the European CE mark approval of FemBloc, the first non-surgical permanent birth control system. This approval marks a significant milestone for the company, allowing the FemBloc system to be marketed across the European Economic Area. The FemBloc system, which offers a safer and more cost-effective alternative to traditional surgical sterilization, is set to be commercially available in Spain and other select European countries. This development underscores Femasys’ commitment to providing innovative solutions in women’s health and is expected to enhance its industry positioning and impact stakeholders positively.

Femasys Appoints Kelley Nicholas as Chief Commercial Officer

On June 17, 2025, Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer to lead the U.S. commercialization of fertility products and expand global partnerships. Ms. Nicholas, with over 25 years of industry experience, is expected to drive revenue growth and strengthen Femasys’ position in women’s health. The company also granted her an option to purchase 100,000 shares of common stock as an inducement for her employment.